Häuser W, Nothacker M
Innere Medizin I (Gastroenterologie, Hepatologie, Stoffwechsel- und Infektionskrankheiten, Psychosomatik), Klinikum Saarbrücken gGmbH, Winterberg 1, 66119, Saarbrücken, Deutschland.
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Technische Universität München, München, Deutschland.
Schmerz. 2017 Jun;31(3):200-230. doi: 10.1007/s00482-017-0209-y.
The regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was planned for April 2017.
The guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n = 8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest.
A systematic search of the literature from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences and applicability of therapies available were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines.
The guidelines are published in several forms, i.e. complete and short scientific versions and clinical practice and patient versions.
纤维肌痛综合征指南（AWMF编号145/004）计划于2017年4月进行定期更新。
该指南由德国疼痛协会协调的13个科学学会和2个患者自助组织制定。成立了8个工作组，共有42名成员，在性别、医学专业知识、在医学或科学层级中的职位以及潜在利益冲突方面保持平衡。
在Cochrane图书馆、MEDLINE、PsycINFO和Scopus数据库中对2010年12月至2016年5月的文献进行了系统检索。根据2009版牛津循证医学中心的分类系统确定证据级别。通过多步骤形式化程序达成共识以确定推荐强度。对现有治疗方法的疗效、风险、患者偏好和适用性进行了权衡。该指南由参与制定指南的学会董事会审查并批准。
该指南以多种形式发布，即完整和简短的科学版本以及临床实践和患者版本。
